We propose a new therapeutic approach with disease-modifying potential: treating patients with severe refractory asthma using their own engineered macrophages.

This technology will drastically change the treatment of severe refractory asthma by reducing the amount and types of medications, the number of visits to doctors and the ER, and health care costs in general. While most therapies inhibit one proinflammatory mediator, this treatment would offer an alternative approach by targeting multiple mediators and enhancing endogenous anti-inflammatory mechanisms.